Dr. Mok Discusses Next Steps With Pembrolizumab in NSCLC
Tony Mok, MD, discusses the next steps for pembrolizumab (Keytruda) as a treatment option for patients with non-small cell lung cancer after the phase III KEYNOTE-042 trial.
Tony Mok, MD, a professor in the department of clinical oncology at the Chinese University of Hong Kong, discusses the next steps for pembrolizumab (Keytruda) as a treatment option for patients with nonsmall cell lung cancer (NSCLC) after the phase III KEYNOTE-042 trial.
The current standard indication has been well-defined by a number of available studies as either monotherapy or in combination, says Mok. One of the next steps includes answering the question of how resistance to single-agent pembrolizumab can be managed.
The next step includes identifying how pembrolizumab can be used as a frame for other immunotherapy agents. Mok says it is still very risky business as there are several negative data that have come out already, but if there is an advantage, it needs to be used.
Emphasizing the Need for NGS in Advanced NSCLC to Determine Treatment
April 23rd 2024During a Case-Based Roundtable® event, Joshua Sabari, MD, led a discussion on the need for next-generation sequencing to determine treatment in patients with EGFR-positive advanced non–small cell lung cancer in the first article of a 2-part series.
Read More
Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC
April 16th 2024At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).
Read More
